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ABSTRACT 
Objective: A stability indicating reverse phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the 
estimation of the combined tablet formulation of lamivudine (LAM) and raltegravir (RAL) in dosage forms and its API. 
Methods: Chromatographic separation was achieved on inertsil ODS C18 5 µm (4.6 X 150 mm) using a mobile phase (MP) consisting of a mixture of 
mixed orthophosphoric acid (OPA): acetonitrile (ACN) in the ratio 50:50 v/v which was determined at 242 nm respectively.  
Results: The assay of LAM and RAL was performed with tablets, and the % assay was found to be 100.12 and 99.89 which shows that the method is 
useful for routine analysis. The linearity of LAM and RAL was found to be linear with a correlation coefficient of 0.998 and 0.999, which shows that 
the method is capable of producing good sensitivity. The retention time of LAM and RAL was 1.99 min and 4.34 min respectively; linearity range 
was found to lie from 15 µg/ml to 75 µg/ml for LAM, 30 µg/ml to 150 µg/ml for RAL with a correlation coefficient of 0.999 respectively. Forced 
degradation studies were conducted in acidic, basic, thermal, photolytic and peroxide where all the degradation peaks were monitored. 
Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of 
LAM and RAL in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of LAM and RAL 
tablet. 
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Human immunodeficiency virus (HIV) is a retrovirus that gradually 
attacks the immune system, which protects the human body against 
illness. Currently, there is no cure for HIV, but with early diagnosis 
and effective antiretroviral (ARV) treatment, people with HIV can 
live a long and normal, healthy life. Therefore, it is important to take 
the correct treatment regularly.  
Lamivudine (LAM) [1-4] belongs to a group of anti-HIV medicines 
called nucleoside reverse transcriptase inhibitors (NRTI). This 
nucleoside analogue is incorporated into viral DNA by HIV reverse 
transcriptase and HBV polymerase, resulting in DNA chain 
termination. The lack of a 3'-OH group in the incorporated 
nucleoside analogue prevents the formation of the 5' to 3' 
phosphodiester linkage essential for DNA chain elongation, and 
therefore, the viral DNA growth is terminated. Its chemical formula 
is 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-
dihydro pyrimidin-2-one and the molecular formula is C8H11N3O3
Raltegravir (RAL) [5-13] is an antiretroviral compound belongs to the 
class of organic compounds known as pyrimidine carboxylic acids and 
derivatives. RAL potassium is a pyrrolidinone derivative and an HIV 
integrase inhibitor that is used in combination with other anti-HIV 
agents for the treatment of HIV infection. Inhibition (INH) of integrase 
prevents insertion of HIV DNA into the human DNA genome, thus 
blocking HIV replication [7, 8]. Its chemical formula is N-[2-[4-[(4-
fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-
2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide and the 
molecular formula is 
S. 
C20H20FKN6O5. 
The previous established methods were found high Rt and increased 
the total run time for analysis. Literature search reveals that only few 
analytical methods were reported for simultaneous estimation of LAM 
and RAL using HPLC [14, 15] method according to the international 
council on harmonization (ICH). There was no stability indicating 
analytical methods reported for simultaneous estimation of LAM and 
RAL. The present study was aimed to develop a simultaneous 
estimation of LAM and RAL along with forced stability studies which 
were found to be simple, precise, accurate and shorter retention time 
which makes this method good for routine analysis in research 
institutions which justify that the developed method is advantageous 
over the existing method. The structures were given in fig. 1.
  
  
(I)       (II) 
Fig. 1: Structure of LAM (I) and RAL (II) 
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MATERIALS AND METHODS 
Chemical and reagents 
Pure samples were obtained as a gift from hetero pharma ltd, 
hyderabad, india. OPA was obtained from finar chemical ltd. 
methanol and ACN were obtained from rankem india ltd.  
Preparation of buffer and mobile phase 
Pipette out 1 ml of 0.1% OPA in 900 ml HPLC water in it. Mix well and 
makeup the volume to 1000 ml with water used as a buffer. Mix a 
mixture of above buffer 500 ml (50%) and 500 ml ACN HPLC (50%) in 
50:50 v/v ratio and degas in ultrasonic water bath for 5 min. 
Preparation of standard and sample solutions 
Accurately transfer 15 mg of LAM and 30 mg of RAL working standard 
into a 10 ml clean dry volumetric flask and sonicate. (Stock solution) 
Further pipette 1 ml of the above stock solution into a 10 ml volumetric 
flask and dilute. Further pipette 3 ml of LAM and RAL of the above stock 
solution into a 10 ml volumetric flask and dilute with diluents.  
Accurately transfer 15 mg of LAM and 30 mg RAL equivalent weight 
of the sample into a 10 ml clean volumetric flask, add about 70 ml of 
diluents and sonicate. (Sample solution) Further pipette 1 ml of the 
above solution into a 10 ml volumetric flask and dilute. Further 
pipette 3 ml of LAM and RAL of solution into a 10 ml volumetric 
flask and dilute with diluents. 
Preparation of mixed standard solution 
Accurately transfer 15 mg of LAM and 30 mg of RAL working 
standard into a 10 ml clean, dry volumetric flask add diluents and 
sonicate to dissolve it completely and make volume up to the mark 
with the same solvent. (Stock solution) Further pipette 1 ml of LAM 
and RAL of the above stock solution into a 10 ml volumetric flask 
and dilute up to the mark with diluents. Further pipette 3 ml of LAM 
and RAL of the above stock solution into a 10 ml volumetric flask 
and dilute up to the mark with diluents. 
Instrumentation 
The proposed method was carried out on inertsil ODS C18 5 µm (4.6 
X 150 mm) and the mobile phase consisted of OPA (pH: 3): ACN 
(50:50 v/v) the column temperature was set 25 °C. From the UV 
spectrum wavelength selected as 242 nm. 
Assay procedure 
Inject 20 µL of the standard, sample into the chromatography system 
and measure the assay of LAM and RAL was performed with tablets.  
Method validation 
The analytical method was validated with respect to parameters 
such as linearity, LOQ, LOD, precision, accuracy, selectivity, recovery 
and ruggedness and was applied for forced degradation studies as 
per the ICH guidelines. [16-18] 
Forced degradation studies  
Acid degradation condition 
Accurately 3.0 ml of stock solution into a 10 ml volumetric flask and 3 ml 
of 0.1N HCl was added. Then, the volumetric flask was kept at 60 °C for 6 
h and then neutralized with 0.1 N NaOH and makeup to 10 ml with 
diluent. The solution was filtered through 0.45μ filter, and then filtrate 
was injected into system and percentage of degradation was calculated. 
Alkali degradation condition 
Accurately 3.0 ml of stock sample into a 10 ml volumetric flask and 
add 3 ml of 0.1N NaOH was added. Then, the volumetric flask was 
kept at 60 °C for 6 h and then neutralized with 0.1N HCl and makeup 
to 10 ml with diluent. The solution was filtered through 0.45μ filter, 
and then the filtrate was injected into the system and percentage of 
degradation was calculated. 
Thermal-induced degradation condition 
3 ml of stock sample was taken in petri dish and kept in hot air oven 
at 110 °C for 24 h. The samples were then placed in a desiccator till 
reaching the room temperature. The content in the flasks was 
dissolved using methanol and diluted up to the mark. Then the 
sample was taken and diluted with diluents and injected and 
percentage of degradation was calculated. 
Photolytic degradation condition 
Accurately 3.0 ml of stock sample was exposed to sunlight for about 
6 h and then the sample diluted with 5 ml of mobile phase and 
percentage of degradation. 
Oxidative degradation condition 
Accurately 3.0 ml of stock sample into a 10 ml volumetric flask, 1 ml 
of 3.0 ml of 3% H2O2
RESULTS AND DISCUSSION 
 was added and the volume was made up to the 
mark with diluent. The volumetric flask was then kept at room 
temperature for 15 min. The solution was filtered through 0.45μ 
filter and then filtrate was injected into the chromatography system 
and the percentage of degradation was calculated. 
There is no official method for this combination so far. However, few 
methods have been reported in either of one or two in this 
combination with some other drugs. For selecting column chiral 
columns of OD52546 and SCDP 52546 inertsil was chosen to 
separate LAM and RAL by injecting system suitability solution with 
the mobile phase at 0.9 ml/min individually. Various solvents 
including water, ACN, phosphate buffer, OPA, and methanol were 
used in different combinations to get good peaks resolutions and 
lesser runtime. Different flow rates from 0.4 to 1 ml/min in gradient 
mode have been studied to achieve a good peak resolution. The 
column temperature was set at 25°, 30° and 35 ° C for optimizing 
according to its effect on peak resolutions and retention times of the 
drug samples. After several initial trials with mixtures of methanol, 
ACN and different buffer in various combinations, a trail with a 
mobile phase mixture of OPA: ACN (50:50 v/v) with 25 °C at 242 nm 
the flow rate was 0.9 ml/min in gradient elution and the injection 
volume was 20 µg/ml of mixed standard solution and the % assay 
was found to be 100.48 and 98.84 which shows that the method was 
useful for routine analysis under the described experimental 
conditions, all the peaks were well defined and free from tailing and 
% recovery values were shown in table 1 and fig. 2. 
System suitability  
It is defined to measure that can generate the result of acceptable 
accuracy and precision. The system suitability was carried out 
after the method development and validation was completed. The 
retention time of LAM and RAL using optimum conditions were 
1.996 min and 4.336 min respectively. Resolution between two 
drugs must be not less than 2. Theoretical plates must be not less 
than 2000. Tailing factor must be not more than 2 as shown in 
table 2.
 
Table 1: Assay and % recovery of LAM and RAL 
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LAM: lamivudine; RAL: raltegravir 
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Fig. 2: Assay chromatogram of LAM and RAL 
 
Table 2: System suitability results of LAM and RAL 
Parameter LAM RAL 
Peak area  42115 215502 
Theoretical plates (N)  2559.08 3511.35 
Retention time (min)  1.996 4.336 
Tailing factor (T) 1.65 1.35 
LAM: lamivudine; RAL: raltegravir 
 
Specificity  
The specificity of the method was evaluated in a placebo solution 
and a blank solution were also prepared. In practice, this can be 
done by spiking the drug substance or product with appropriate 
levels of excipients and demonstrating that the assay results are 
unaffected by the presence of these extraneous materials. Optimized 
chromatogram of LAM and RAL are shown in fig. 3.
 
 
Fig. 3: Specificity chromatogram of LAM and RAL 
 
Linearity 
From the stock solution, inject each level into the chromate-
graphy system and measure the peak area. Plot a graph of peak 
area versus concentration and calculate the correlation 
coefficient. The correlation coefficient obtained was 0.99 which 
is in the acceptance limit. The linearity range was found to lie 
from 15 µg/ml to 75 µg/ml of LAM 30 µg/ml to 150 µg/ml of 
RAL and chromatograms were shown below as shown in fig. 4-5 
and table 3.
 
Table 3: Linearity data of LAM and RAL 
LAM RAL 
Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area 
15 14891 30 67496 
30 30568 60 151923 
45 43243 90 223324 
60 59103 120 304753 
75 71989 150 374626 
LAM: lamivudine; RAL: raltegravir 
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Fig. 4: Linearity graph of LAM 
 
 
Fig. 5: Linearity graph of RAL
Table 4: Precision data of LAM and RAL 
Parameter LAM RAL 
Retention time (min) Peak area Retention time (min) Peak area 
1 1.991 48270 4.365 218798 
2 1.984 46977 4.385 216905 
3 1.989 46914 4.362 216459 
4 1.991 46722 4.359 221802 
5 1.995 47013 4.366 218749 
Average (min) 1.984 47179.2 4.355 21852.6 
SD  0.002 620 0.002 2106.8 
% RSD  1.32 1.31 0.92 0.96 
n=5; LAM: lamivudine; RAL: raltegravir; SD: standard deviation; RSD: relative standard deviation 
 
Precision  
The standard solution was injected for five times and measured the 
area in HPLC. % RSD for sample should be NMT 2. One dilution of all 
the drugs in six replicates was injected into HPLC system and was 
analyzed and the results were shown in the table 4. 
LOD and LOQ 
LOD and LOQ for LAM and RAL were estimated and as the amounts 
for the signal to noise ratios were found to be 3:1 and 10:1 
respectively. LOD values for LAM and RAL were 2.96 and 2.95 s/n 
ratio. LOQ values for LAM and RAL were 9.96 and 9.98 s/n ratio. 
Signal to noise ratio shall be 3 for LOD and 10 for LOQ solution. 
Method precision  
The standard solution was injected for five times and measured the 
area for all five injections. The precision of the method was carried 
out for both sample solutions as described under experimental 
work. The corresponding chromatograms and results were below as 
table 5.
  
Table 5: Method precision data of LAM and RAL 
Parameter LAM RAL 
Retention time (min) Peak area Retention time (min)  Peak area 
1 2.004 48270 4.374 218798 
2 1.999 46977 4.356 216905 
3 1.993 46914 4.358 216459 
4 1.992 46722 4.356 221802 
5 1.990 47013 4.354 218749 
Average (min) 1.994 47179.2 4.358 218542.6 
SD  0.004 620 0.005 2106.8 
% RSD  0.31 1.31 0.96 0.96 
n=5; LAM: lamivudine; RAL: raltegravir; SD: standard deviation; RSD: relative standard deviation 
 
Table 6: Ruggedness data for a sample of LAM and RAL 
Parameter LAM RAL 
Retention time (min) Peak area Retention time (min) Peak area 
1 1.996 45921 4.382 213936 
2 2.001 47289 4.382 219057 
3 1.992 46249 4.374 218423 
4 1.992 47758 4.75 222496 
5 1.990 47193 4.61 219155 
Average (min) 1.992 46838.17 4.352 218181 
SD  0.004 694.5 0.005 2935.6 
% RSD  0.31 1.48 0.96 1.35 
n=5; LAM: lamivudine; RAL: raltegravir; SD: standard deviation; RSD: relative standard deviation 
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Ruggedness  
To evaluate the ruggedness of the method, precision was 
performed on a different day within the laboratory. %RSD of five 
different sample solutions should not more than 2. There was no 
significant change in assay content and system suitability 
parameters at different conditions of ruggedness like day to day 
and system to system variation. The standard solution was 
injected for five times and measured the area for all five 
injections as shown in tables 6. 
Accuracy  
For accuracy determination, three different concentrations were 
prepared separately, i.e. 50%, 100% and 150% for the analyst and 
chromatograms were recorded for the same. Calculate the amount 
found and amount added for LAM and RAL and calculate the 
individual recovery and mean recovery values. The percentage 
recovery was found to be within the limit (97-103%). 
The results obtained for recovery at 50%, 100%, 150% are within the 
limits. Hence method is accurate. The results were given in tables 7.
 
Table 7: Recovery data of LAM and RAL 
Drug Sample  Amount added (μg/ml) Amount found (μg/ml) Area % Mean % Average 
LAM 50% 7.5 7.62 22056 100.58 100.12 
100% 15 14.85 43140 99.18 
150% 22.5 22.52 66628 100.60 
RAL 50% 15 14.83 106479 98.94 99.89 
100% 30 29.88 214516 99.67 
150% 45 45.47 326302 101.07 
 n=3;LAM: lamivudine; RAL: raltegravir 
 
Robustness  
Standard solution 45 µg/ml and 90 µg/ml of LAM and RAL was 
prepared and analysed using the varied flow rate and mobile 
phase composition along with the actual mobile phase 
composition in the method. System suitability parameters were 
compared with that of method precision. The retention time, 
plate count, tailing factor obtained for a change of flow rate, 
variation in mobile phase was found to be within the acceptance 
criteria. Hence the method is robust. The result of the robustness 
study of the developement assay method was established in 
table 8.
  
Table 8: Robustness for LAM and RAL 
Drug Flow rate 
(ml/min) 
System suitability USP Change in 
mobile phase 
System suitability USP 
Plate Tailing Plate Tailing 
LAM 0.8 2736.08 1.53 10% less 2732.24 1.54 
0.9 2559.08 1.65 actual 2559.08 1.65 
1.0 2540.88 1.53 10% more 2865.60 1.66 
RAL 0.8 3910.92 1.31 10% less 3884.75 1.29 
0.9 3511.35 1.35 actual 3511.35 1.35 
1.0 3456.84 1.29 10% more 4002.13 1.36 
 n=3;LAM: lamivudine; RAL: raltegravir 
 
Table 9: Degradation studies results for LAM and RAL 
Condition LAM RAL 
Area % Degraded Area % Degraded 
Control 45921 - 213936 - 
Acid 45623.56 5.25 213754.25 5.04 
Alkali 45589.54 5.06 213624.87 5.17 
Peroxide 45423.69 5.87 213542.24 6.25 
Thermal 45752.84 3.23 213564.36 2.54 
Photo 45856.56 1.15 213896.21 1.13 
LAM: lamivudine; RAL: raltegravir 
 
 
Fig. 6: Acid degradation of LAM and RAL 
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Forced degradation studies  
The stability studies were determined by applying the physical 
stress to the product. Results in forced degradation were shown in 
table 9 and blank was recorded. The results of forced degradation 
studies for the simultaneous estimation of LAM and RAL were in 
limits, and respective chromatograms were represented. It was 
observed that the drug degrades as shown by the decreased areas 
in the peaks when compared to peak areas of the same 
concentration of the non-degraded drug, with additional 
degradation peaks. Percent degradation was calculated by 
comparing the areas of the degraded peaks at each degradation 
condition with the corresponding areas of the peaks of both the 
drugs under non-degradation condition. Degradation studied were 
performed and it was observed that no interference of degradants 
as shown in fig. 6-10.
 
 
Fig. 7: Alkali degradation of LAM and RAL 
 
 
Fig. 8: Thermal degradation of LAM and RAL 
 
 
Fig. 9: Photolytic degradation of LAM and RAL 
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Fig. 10: Oxidative degradation of LAM and RAL 
 
CONCLUSION 
A simple and selective RP-HPLC method was described for the 
determination of LAM and RAL dosage forms. The retention time of 
LAM and RAL was 1.99 min and 4.34 min respectively. The linearity 
of LAM and RAL was found to be linear with a correlation coefficient 
of 0.998 and 0.999. The acceptance criteria of precision were RSD 
should be not more than 2.0% and the method shows precision 1.31 
and 0.96 for LAM and RAL which shows that the method was 
precise. The results of forced degradation studies for the 
simultaneous estimation of LAM and RAL were in limits, and 
respective chromatograms were represented. Hence the method 
was successfully applied for degradation studies, and HPLC method 
for simultaneous estimation of LAM and RAL was novel, simple, 
precise, accurate, robust and cost-effective method.  
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